Arslan Alaettin, Guney Yildiz, Cihan Yasemin Benderli, Cetindag Mehmet Faik
Kayseri Education and Research Hospital, Department of Radiation Oncology, Kayseri, Turkey.
J BUON. 2014 Jul-Sep;19(3):724-32.
To evaluate the clinical characteristics, management approaches and life expectancy in pediatric patients with neuroepithelial glial tumors except ependymal tumors.
Between January 2003 and August 2008, 48 patients (30 boys, 18 girls; mean age: 10.9 ± 4.6 years) who were diagnosed with neuroepithelial glial tumors except ependymal tumors and underwent curative radiotherapy (RT) for inoperable, postoperative adjuvant or palliative for residual/recurrent disease at Dr. Abdurahman Yurtsalan Ankara Oncology Education and Research Hospital, Radiation Oncology Clinic, were retrospectively analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated in relation to sex, previous surgical procedure, pathological diagnosis, low/high grade and the histopathological grade of disease.
The mean follow-up was 28.8 ± 4.8 months. The mean and median PFS were 36.2 months and 20 months, respectively, while mean and median OS were 40.3 months and 23 months, respectively. One-year PFS and OS were 65.8% and 71%, respectively, whereas 3-year PFS and OS were 36.3% and 42.3%, respectively. Univariate Cox regression model and Log-Rank test revealed no statistical significance. Prolonged PFS and OS were observed in boys compared to girls, those who underwent total/gross total resection compared to subtotal resection, those with low grade tumors compared to high-grade tumors, and those with histopathological grade I disease compared to grade IV disease (p>0.05). The PFS and OS times were shortened in patients who developed side effects at any time following surgery and RT, compared to those without any side effects (p>0.05).
Low-grade disease and total/gross total resection prolong PFS and OS in patients with childhood glial tumors.
评估除室管膜瘤外的小儿神经上皮性胶质肿瘤患者的临床特征、治疗方法及预期寿命。
回顾性分析2003年1月至2008年8月期间在阿卜杜勒拉赫曼·于尔察兰安卡拉肿瘤教育与研究医院放射肿瘤诊所被诊断为除室管膜瘤外的神经上皮性胶质肿瘤,并因无法手术、术后辅助治疗或对残留/复发性疾病进行姑息性治疗而接受根治性放疗(RT)的48例患者(30例男孩,18例女孩;平均年龄:10.9±4.6岁)。根据性别、既往手术方式、病理诊断、低/高级别以及疾病的组织病理学分级评估无进展生存期(PFS)和总生存期(OS)。
平均随访时间为28.8±4.8个月。平均PFS和中位PFS分别为36.2个月和20个月,而平均OS和中位OS分别为40.3个月和23个月。1年PFS和OS分别为65.8%和71%,而3年PFS和OS分别为36.3%和42.3%。单因素Cox回归模型和Log-Rank检验显示无统计学意义。与女孩相比,男孩、接受全切除/大体全切除的患者与次全切除的患者相比、低级别肿瘤患者与高级别肿瘤患者相比、组织病理学I级疾病患者与IV级疾病患者相比,观察到PFS和OS延长(p>0.05)。与无任何副作用的患者相比,在手术和放疗后任何时间出现副作用的患者的PFS和OS时间缩短(p>0.05)。
低级别疾病以及全切除/大体全切除可延长儿童胶质肿瘤患者的PFS和OS。